Parathyroid hormone (1-84) and teriparatide in the treatment of postmenopausal osteoporosis

被引：5
|
作者：
Bogado, Cesar E. [1 ]
Massari, Fabio E. [1 ]
Zanchetta, Jose R [1 ]
机构：
[1] Inst Investigaciones Metabol, Libertad 836,C1012, Buenos Aires, DF, Argentina
来源：
WOMENS HEALTH | 2006年 / 2卷 / 03期
关键词：
bone anabolic; agents; bone mineral density; osteoporosis treatment; parathyroid hormone; teriparatide; vertebral fractures;
D O I：
10.2217/17455057.2.3.447
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Osteoporosis-related fractures are a major public health problem worldwide. Antiresorptive drugs, which work principally by suppressing bone resorption, are the established therapeutic approach for the prevention of fragility fractures in patients with osteoporosis. Parathyroid hormone and its analogs represent a new class of agents with anabolic effects on the skeleton. The results of double-blind, randomized, placebo-controlled trials have shown that both the full length, 84 amino acid parathyroid hormone and teriparatide, the parathyroid hormone fragment (1-34) increase bone mineral density and reduce the risk of fracture when administered intermittently to postmenopausal osteoporotic women. Therefore, these drugs should be considered an alternative therapy in postmenopausal osteoporosis.
引用
收藏
页码：447 / 457
页数：11
相关论文
共 50 条
  • [1] Is parathyroid hormone (1-84) a safe and effective treatment for postmenopausal osteoporosis?
    Leder, Benjamin Z.
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (11): : 746 - 747
  • [2] Parathyroid hormone (1-84) and treatment of osteoporosis
    Shrader, SP
    Ragucci, KR
    [J]. ANNALS OF PHARMACOTHERAPY, 2005, 39 (09) : 1511 - 1516
  • [3] Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women
    Jodar-Gimeno, Esteban
    [J]. CLINICAL INTERVENTIONS IN AGING, 2007, 2 (01) : 163 - 174
  • [4] Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women
    Adami, Silvano
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (11) : 3259 - 3274
  • [5] The use of teriparatide and PTH(1-84) for the treatment of osteoporosis
    Wagman R.B.
    Miller P.D.
    [J]. Clinical Reviews in Bone and Mineral Metabolism, 2006, 4 (4): : 277 - 290
  • [6] Update on the efficacy, safety, and adherence to treatment of full length parathyroid hormone, PTH (1-84), in the treatment of postmenopausal osteoporosis
    Pietrogrande, Luca
    [J]. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2009, 1 : 193 - 203
  • [7] Is parathyroid hormone (1–84) a safe and effective treatment for postmenopausal osteoporosis?
    Benjamin Z Leder
    [J]. Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 : 746 - 747
  • [8] Consistency of Bone Turnover Marker and Calcium Responses to Parathyroid Hormone (1-84) Therapy in Postmenopausal Osteoporosis
    Schafer, Anne L.
    Palermo, Lisa
    Bauer, Douglas C.
    Bilezikian, John P.
    Sellmeyer, Deborah E.
    Black, Dennis M.
    [J]. JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (01) : 68 - 73
  • [9] Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide
    Johannes Pleiner-Duxneuner
    Elisabeth Zwettler
    Eleftherios Paschalis
    Paul Roschger
    Valerie Nell-Duxneuner
    Klaus Klaushofer
    [J]. Calcified Tissue International, 2009, 85 (5) : 463 - 463
  • [10] Treatment of Osteoporosis with Parathyroid Hormone and Teriparatide
    Pleiner-Duxneuner, Johannes
    Zwettler, Elisabeth
    Paschalis, Eleftherios
    Roschger, Paul
    Nell-Duxneuner, Valerie
    Klaushofer, Klaus
    [J]. CALCIFIED TISSUE INTERNATIONAL, 2009, 84 (03) : 159 - 170
12345